Star’s Electra spinout turning SIRP proteins into depletion handles
True North alums reunite to scale their rare disease mAb playbook through a series of newcos, starting with Electra
The first in a series of spinouts from Star targeting biology shared by multiple diseases, Electra is leveraging insights into the SIRP protein family to stop pathogenic myeloid and T cell activity via a clinical-stage lead program, with a series of preclinical assets behind it.
Electra Therapeutics Inc. and its parent company Star Therapeutics both emerged from stealth Feb. 16. The companies reunite leadership and investors from True North Therapeutics Inc., whose mAb Enjaymo sutimlimab is now marketed by Sanofi (Euronext:SAN; NASDAQ:SNY) for a rare complement-mediated disease after the biotech’s 2017 acquisition by Bioverativ Inc. for $400 million up front and up to $425 million in milestones. Sanofi acquired Bioverativ for $11.6 billion in 2018. ...